Kubient, Inc.

2023 Q2 Form 10-Q Financial Statement

#000141057823001352 Filed on May 22, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.83M
YoY Change -42.89%
Cash & Equivalents $11.83M
Short-Term Investments
Other Short-Term Assets $313.6K
YoY Change -23.86%
Inventory
Prepaid Expenses
Receivables $98.13K
Other Receivables $0.00
Total Short-Term Assets $12.24M
YoY Change -47.86%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K
YoY Change 0.0%
Total Long-Term Assets $10.00K
YoY Change -99.7%
TOTAL ASSETS
Total Short-Term Assets $12.24M
Total Long-Term Assets $10.00K
Total Assets $12.25M
YoY Change -54.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.163M
YoY Change -67.01%
Accrued Expenses $448.8K
YoY Change -37.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.722M
YoY Change -61.27%
LONG-TERM LIABILITIES
Long-Term Debt $78.90K
YoY Change 1.92%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $78.90K
YoY Change -21.72%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.722M
Total Long-Term Liabilities $78.90K
Total Liabilities $1.800M
YoY Change -60.4%
SHAREHOLDERS EQUITY
Retained Earnings -$42.67M
YoY Change 41.24%
Common Stock $145.00
YoY Change 1.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.45M
YoY Change
Total Liabilities & Shareholders Equity $12.25M
YoY Change -54.26%

Cashflow Statement

Concept 2023 Q2 2023 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001729750
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14440464
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14256159
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Kubient, Inc.
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14515940
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14456035
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39441
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1808844
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
500 7th Avenue
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
8th Floor
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10018
CY2023Q1 dei City Area Code
CityAreaCode
800
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
409-9456
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11827956
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14739484
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
98132
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
135658
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
313606
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
346935
CY2023Q1 us-gaap Assets Current
AssetsCurrent
12239694
CY2022Q4 us-gaap Assets Current
AssetsCurrent
15222077
CY2023Q1 us-gaap Deferred Costs
DeferredCosts
10000
CY2022Q4 us-gaap Deferred Costs
DeferredCosts
10000
CY2023Q1 us-gaap Assets
Assets
12249694
CY2022Q4 us-gaap Assets
Assets
15232077
CY2023Q1 kbnt Accounts Payable Supplier Current
AccountsPayableSupplierCurrent
386497
CY2022Q4 kbnt Accounts Payable Supplier Current
AccountsPayableSupplierCurrent
673781
CY2023Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
776545
CY2022Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
816190
CY2023Q1 kbnt Accrued And Other Liabilities Current Other Than Interest Payable
AccruedAndOtherLiabilitiesCurrentOtherThanInterestPayable
557964
CY2022Q4 kbnt Accrued And Other Liabilities Current Other Than Interest Payable
AccruedAndOtherLiabilitiesCurrentOtherThanInterestPayable
830365
CY2023Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
567
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
28403
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1721573
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2348739
CY2023Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
78900
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
78900
CY2023Q1 us-gaap Liabilities
Liabilities
1800473
CY2022Q4 us-gaap Liabilities
Liabilities
2427639
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
95000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
95000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14515940
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14456035
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
145
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
145
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
53115414
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
53004967
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-42666338
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-40200674
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
10449221
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12804438
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12249694
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15232077
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
11748
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1245304
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
735033
CY2022Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1333010
CY2023Q1 us-gaap Communications And Information Technology
CommunicationsAndInformationTechnology
519194
CY2022Q1 us-gaap Communications And Information Technology
CommunicationsAndInformationTechnology
1155699
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1243384
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2182549
CY2022Q1 kbnt Loss Accrual On Customer Contract
LossAccrualOnCustomerContract
789605
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
2497611
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
5460863
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2485863
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4215559
CY2023Q1 us-gaap Interest Expense
InterestExpense
2446
CY2022Q1 us-gaap Interest Expense
InterestExpense
3872
CY2023Q1 us-gaap Interest Income Other
InterestIncomeOther
4445
CY2022Q1 us-gaap Interest Income Other
InterestIncomeOther
2291
CY2022Q1 kbnt Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
589622
CY2023Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
18200
CY2022Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
26
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
20199
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
588067
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2465664
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3627492
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14440464
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14256159
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12804438
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
108206
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2241
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2465664
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
10449221
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25450260
CY2022Q1 kbnt Shares Issued And Forfeited During Period Value
SharesIssuedAndForfeitedDuringPeriodValue
-18683
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
430361
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2295
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3627492
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
22236741
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-2465664
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-3627492
CY2023Q1 us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
9471
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
162221
CY2022Q1 kbnt Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
589622
CY2023Q1 us-gaap Restricted Stock Expense
RestrictedStockExpense
108206
CY2022Q1 us-gaap Restricted Stock Expense
RestrictedStockExpense
429811
CY2023Q1 kbnt Stock Options Plan Expense
StockOptionsPlanExpense
2241
CY2022Q1 kbnt Stock Options Plan Expense
StockOptionsPlanExpense
2295
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-28055
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
60930
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-33329
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-590661
CY2023Q1 kbnt Increase Decrease In Accounts Payable Suppliers
IncreaseDecreaseInAccountsPayableSuppliers
-287284
CY2022Q1 kbnt Increase Decrease In Accounts Payable Suppliers
IncreaseDecreaseInAccountsPayableSuppliers
630026
CY2023Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-39645
CY2022Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
391034
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-190221
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1532150
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-27836
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-369195
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2829348
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3973341
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7520
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7520
CY2022Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
109270
CY2023Q1 kbnt Repayment Of Financed Director And Officer Insurance Premiums
RepaymentOfFinancedDirectorAndOfficerInsurancePremiums
82180
CY2022Q1 kbnt Repayment Of Financed Director And Officer Insurance Premiums
RepaymentOfFinancedDirectorAndOfficerInsurancePremiums
108788
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-82180
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-218058
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2911528
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4198919
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14739484
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24907963
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11827956
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20709044
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
3215
CY2022Q1 kbnt Share Issued And Forfeited During Period Value
ShareIssuedAndForfeitedDuringPeriodValue
-18683
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11827956
CY2023Q1 kbnt Working Capital
WorkingCapital
10518121
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2465664
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2829348
CY2023Q1 kbnt Cash In Bank In Excess Of Federal Deposit Insurance Corporation Insured Limits
CashInBankInExcessOfFederalDepositInsuranceCorporationInsuredLimits
11827956
CY2022Q4 kbnt Cash In Bank In Excess Of Federal Deposit Insurance Corporation Insured Limits
CashInBankInExcessOfFederalDepositInsuranceCorporationInsuredLimits
14739484
CY2022Q1 kbnt Loss Accrual On Customer Contract
LossAccrualOnCustomerContract
789605
CY2023Q1 us-gaap Energy Marketing Contract Liabilities Current
EnergyMarketingContractLiabilitiesCurrent
567
CY2022Q4 us-gaap Energy Marketing Contract Liabilities Current
EnergyMarketingContractLiabilitiesCurrent
531
CY2022Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
0
CY2023Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
0
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5600812
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6380001
CY2023Q1 kbnt Class Of Warrant Or Right Number Of Warrants Exercisable
ClassOfWarrantOrRightNumberOfWarrantsExercisable
368711
CY2023Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2023Q1 kbnt Class Of Warrants Or Rights Number Of Securities Called By Warrants Or Right
ClassOfWarrantsOrRightsNumberOfSecuritiesCalledByWarrantsOrRight
368711
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.50
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
215761
CY2023Q1 kbnt Accrued Payroll
AccruedPayroll
89375
CY2023Q1 kbnt Financed Director And Officer Insurance Premiums
FinancedDirectorAndOfficerInsurancePremiums
84240
CY2022Q4 kbnt Financed Director And Officer Insurance Premiums
FinancedDirectorAndOfficerInsurancePremiums
168480
CY2023Q1 kbnt Accrued Supplier Expenses
AccruedSupplierExpenses
44448
CY2022Q4 kbnt Accrued Supplier Expenses
AccruedSupplierExpenses
44949
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
170332
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
49832
CY2023Q1 kbnt Accrued Commissions
AccruedCommissions
702
CY2022Q4 kbnt Accrued Commissions
AccruedCommissions
4181
CY2023Q1 kbnt Credit Card Payable
CreditCardPayable
51650
CY2022Q4 kbnt Credit Card Payable
CreditCardPayable
226679
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
8734
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
11220
CY2023Q1 kbnt Accrued Warrant Exercise Issuance Costs Current
AccruedWarrantExerciseIssuanceCostsCurrent
83519
CY2022Q4 kbnt Accrued Warrant Exercise Issuance Costs Current
AccruedWarrantExerciseIssuanceCostsCurrent
83519
CY2023Q1 kbnt Accrued Expenses And Other Current Liabilities Others
AccruedExpensesAndOtherCurrentLiabilitiesOthers
24964
CY2022Q4 kbnt Accrued Expenses And Other Current Liabilities Others
AccruedExpensesAndOtherCurrentLiabilitiesOthers
25744
CY2023Q1 kbnt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
557964
CY2022Q4 kbnt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
830365
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
110447
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
432106
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1152375
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D

Files In Submission

Name View Source Status
0001410578-23-001352-index-headers.html Edgar Link pending
0001410578-23-001352-index.html Edgar Link pending
0001410578-23-001352.txt Edgar Link pending
0001410578-23-001352-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
kbnt-20230331.xsd Edgar Link pending
kbnt-20230331x10q.htm Edgar Link pending
kbnt-20230331x10q001.jpg Edgar Link pending
kbnt-20230331xex31d1.htm Edgar Link pending
kbnt-20230331xex31d2.htm Edgar Link pending
kbnt-20230331xex32d1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
kbnt-20230331_cal.xml Edgar Link unprocessable
kbnt-20230331_pre.xml Edgar Link unprocessable
kbnt-20230331_def.xml Edgar Link unprocessable
kbnt-20230331_lab.xml Edgar Link unprocessable
kbnt-20230331x10q_htm.xml Edgar Link completed
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending